EUVIMEDEUVIMED entdecken
Open Access

SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [ 177 Lu]Lu-DOTATATE

Johan Blakkisrud, Avery B Peterson, Scott J Wildermann, Griffen Kingkiner, Ka Kit Wong, Chang Wang, Kirk A Frey, Caroline Stokke, Yuni K Dewaraja

Journal of Nuclear Medicine · 2024

DOI: 10.2967/jnumed.123.266843 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Johan Blakkisrud und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, University of Michigan, Ann Arbor, Michigan; johbla@ous-hf.no. Hauptthemen laut MEDLINE: Octreotide, Organometallic Compounds, Single Photon Emission Computed Tomography Computed Tomography, Bone Marrow. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hematologic toxicity, although often transient, is the most common limiting adverse effect during somatostatin peptide receptor radionuclide therapy. This study investigated the association between Monte Carlo-derived absorbed dose to the red marrow (RM) and hematologic toxicity in patients being treated for their neuroendocrine tumors.

Methods

Twenty patients each receiving 4 treatment cycles of [177Lu]Lu-DOTATATE were included. Multiple-time-point 177Lu SPECT/CT imaging-based RM dosimetry was performed using an artificial intelligence-driven workflow to segment vertebral spongiosa within the field of view (FOV). This workflow was coupled with an in-house macroscale/microscale Monte Carlo code that incorporates a spongiosa microstructure model. Absorbed dose estimates to RM in lumbar and thoracic vertebrae within the FOV, considered as representations of the whole-body RM absorbed dose, were correlated with hematologic toxicity markers at about 8 wk after each cycle and at 3- and 6-mo follow-up after completion of all cycles.

Results

The median of absorbed dose to RM in lumbar and thoracic vertebrae within the FOV (D median,vertebrae) ranged from 0.019 to 0.11 Gy/GBq. The median of cumulative absorbed dose across all 4 cycles was 1.3 Gy (range, 0.6-2.5 Gy). Hematologic toxicity was generally mild, with no grade 2 or higher toxicity for platelets, neutrophils, or hemoglobin. However, there was a decline in blood counts over time, with a fractional value relative to baseline at 6 mo of 74%, 97%, 57%, and 97%, for platelets, neutrophils, lymphocytes, and hemoglobin, respectively. Statistically significant correlations were found between a subset of hematologic toxicity markers and RM absorbed doses, both during treatment and at 3- and 6-mo follow-up. This included a correlation between the platelet count relative to baseline at 6-mo follow up: D median,vertebrae (r = -0.64, P = 0.015), D median,lumbar (r = -0.72, P = 0.0038), D median,thoracic (r = -0.58, P = 0.029), and D average,vertebrae (r = -0.66, P = 0.010), where D median,lumbar and D median,thoracic are median absorbed dose to the RM in the lumbar and thoracic vertebrae, respectively, within the FOV and D average,vertebrae is the mass-weighted average absorbed dose of all vertebrae.

Conclusion

This study found a significant correlation between image-derived absorbed dose to the RM and hematologic toxicity, including a relative reduction of platelets at 6-mo follow up. These findings indicate that absorbed dose to the RM can potentially be used to understand and manage hematologic toxicity in peptide receptor radionuclide therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OctreotideOrganometallic CompoundsSingle Photon Emission Computed Tomography Computed TomographyBone MarrowNeuroendocrine TumorsHumansMaleFemaleMiddle AgedAgedAdultRadiometryRadiation DosageMonte Carlo MethodHematologic Diseases

Stichwörter der Autor:innen

[177Lu]Lu-DOTATATEpeptide receptor radionuclide therapyradiopharmaceutical therapyred marrow dosimetrytheranostics

Substanzen

OctreotideOrganometallic Compoundslutetium Lu 177 dotatate

Autor:innen und Institutionen

  • Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, University of Michigan, Ann Arbor, Michigan; johbla@ous-hf.no.
  • Department of Physics and Computational Radiology, Oslo University Hospital, Oslo, Norway.
  • Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, University of Michigan, Ann Arbor, Michigan.
  • Department of Radiation Oncology, Wayne State University, Detroit, Michigan.
  • Department of Nuclear Engineering and Radiologic Science, University of Michigan, Ann Arbor, Michigan.
  • Department of Biostatistics, University of Michigan, Ann Arbor, Michigan; and.

Förderung

  • NCI NIH HHS

Zitieren

APA

Blakkisrud, J., Peterson, A. B., Wildermann, S. J., Kingkiner, G., Wong, K. K., Wang, C., Frey, K. A., Stokke, C., & Dewaraja, Y. K. (2024). SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [ 177 Lu]Lu-DOTATATE. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.266843

Vancouver

Blakkisrud J, Peterson AB, Wildermann SJ, Kingkiner G, Wong KK, Wang C, et al. SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [ 177 Lu]Lu-DOTATATE. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.266843

BibTeX
@article{Blakkisrud2024,
  author = {Blakkisrud, Johan and Peterson, Avery B and Wildermann, Scott J and Kingkiner, Griffen and Wong, Ka Kit and Wang, Chang and Frey, Kirk A and Stokke, Caroline and Dewaraja, Yuni K},
  title = {SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [ 177 Lu]Lu-DOTATATE},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  doi = {10.2967/jnumed.123.266843}
}
Kostenlos starten →